-Mean (point), maximum (triangle) and minimum (square) value and standard deviation (line) of the difference between TG43 and TG186 results, for the dose points, bladder and rectum.
Results:
In all cases, the obtained dose following the TG186 method was lower than that obtained with the TG43 recommendations. Moreover, differences were found between the two described applicators (that had never been noticed with the TG43). The prescribed dose and the dose to 2cc of the bladder and rectum varied as follows (figure 1): between 0.4% and 2.7% for the prescribed dose, between 0.6% and 2.5% for the bladder and between 0.9% and 2.7% for the rectum.
Conclusion:
Differences were found between the dosimetry plans obtained with the TG43 and our model based dose calculation algorithm following TG186 recommendations. A deeper knowledge of this new algorithm and its applications in a more accurate dose calculation will be the future of this work.
PO-0962
Adjuvant brachytherapy as a part of a multimodal treatment for high-grade uterine sarcoma P. Annède 1 Gustave Roussy, Radiation Oncology, Villejuif, France 1 , P. Maroun 1 , C. Petit 1 , R. Mazeron 1 , I. Dumas 1 , C. Genestie 2 , P. Pautier 3 , C. Chargari 1 , C. Haie-Meder 1 2 Gustave Roussy, Pathology, Villejuif, France 3 Gustave Roussy, Gynecology, Villejuif, France Purpose or Objective: To assess the loco-regional efficacy and toxicity of a multimodal strategy including brachytherapy (BT) as part of the adjuvant treatment of localized highgrade uterine sarcoma.
Material and Methods:
A single center retrospective analysis of patients (pts) treated from 1985 to 2015 was conducted. 104 pts with high-grade uterine sarcoma were identified. 80 pts had leiomyosarcomas, 17 undifferentiated sarcomas, 3 rhabdomyosarcomas and 1 high grade adenosarcoma. 10 pts had a microscopic (n = 8) or macroscopic (n = 2) positive surgical margins.
Results:
The median follow-up time was 5.4 years. 57 pts underwent perioperative chemotherapy. 102 pts underwent postoperative external beam radiation therapy (EBRT) followed by a BT boost, and 2 pts received BT without EBRT. The median pelvic EBRT dose was 45 Gy (range 25-50.4). 69 pts were treated with HDR BT (median dose = 10Gy), 33 with LDR (median dose = 15Gy), and 2 with PDR without EBRT (median dose = 60Gy). The 5-year local-regional failure-free survival and overall survival rates were 93% (CI 95% = 87-99%), and 73%(CI 95% = 0.63-0.84%) respectively. Only 5 vaginal recurrences were identified. 2 pts presented grade 3 late toxicity, all other side effects were grade 2 or less.
Conclusion: Adjuvant BT included in a multimodal treatment was associated with a high loco-regional control rate and acceptable acute and late toxicity in patient with localized high-grade uterine sarcoma. Purpose or Objective: This study aims to demonstrate effective and non-invasive virtual pre-planning using week 5 MRI without the need of applicator in-situ for image-guided cervix brachytherapy.
PO-0963 Effectiveness of week 5 MRI virtual preplanning for Image-Guided Brachytherapy for cervical cancers
Material and Methods: 15 patients with stage IB2-IVA cervical cancers were treated at our institution in January to October 2015 using chemoradiation and brachytherapy. All patients received whole pelvic radiotherapy 45Gy in 25 fractions over 5 weeks, with concurrent weekly cisplatin 40mg/m 2 for up to 6 cycles, followed by additional parametrial boosting 10-16G in 5-8 fractions over 1-2 weeks. HDR brachytherapy using Ir-192 was performed in all patients at week 6 and 7, using Vienna schedule 3 of 2 weekly insertions with 2 consecutive fractions per week, and first insertion was approximately 4-7 days after completion of whole pelvic radiotherapy. Treatment aim was 7Gy to HRCTV D90 each for 4 fractions. Week 5 MRI was performed in all patients, and HRCTVwk5 was contoured. Virtual preplanning was done with proposed applicators according to prebrachytherapy clinical assessment of dedicated oncologist. An estimated D90 for HRCTV (D90wk5) was then compared with the actual D90 HRCTV at week 6 and week 7. Maximum diameter for HRCTV at week 6 were measured, and plans with suboptimal coverage after brachytherapy was regarded as having cumulative D90 HRCTV </= 83.9Gy.
Results:
All 15 patients completed chemoradiation with schedule indicated. The choice of applicators was dependent on geometry of tumor (tandem and ovoids or ring or cylinder). Five patients were noted to have suboptimal tumor coverage, with cumulative D90 HRCTV dose ranging from 40.7 to 70.7 Gy. The corresponding maximum diameter of week 6 HRCTV was found to have significant correlation with cumulative HRCTV D90, and a cut-off value of tumor diameter 4.63cm could predict cumulative dose of 83.9 Gy. Based on the initial results, 2.5cm tumor radius from midline was decided to be the cut-off for using interstitial needles to improve dosimetry. With the implementation of interstital needles in September 2015, one patient received needle insertion based on virtual preplanning with estimated needle position and depth of insertion from week 5 MRI. Estimated HRCTV D90wk5 tumor radius from midline was 3.6cm. Improvement of HRCTV D90wk5 from 4.9Gy and 8.33 Gy was noted before and after virtual needle insertion. The subsequent week 6 and 7 brachytherapy using the preplanning information showed excellent correlation in terms of HRCTV D90 dosimetry, with cumulative HRCTVactual 89.2Gy (dose per fraction was 7.8, 7.5, 8.6 and 8.6Gy respectively).
Conclusion:
This study demonstrates the effectiveness of a non-invasive method using week 5 MRI for virtual preplanning, with accurate estimation of HRCTV, that can guide needle insertion diligently. Tumor radius of 2.5cm was proven to be a good reference to select patients for interstitial needle insertion.
